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Abstract
BACKGROUND—We investigated whether combination therapy with a statin plus a fibrate, as
compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with
type 2 diabetes mellitus who were at high risk for cardiovascular disease.
METHODS—We randomly assigned 5518 patients with type 2 diabetes who were being treated
with open-label simvastatin to receive either masked fenofibrate or placebo. The primary outcome
was the first occurrence of nonfatal myocardial infarction, nonfatal stroke, or death from
cardiovascular causes. The mean follow-up was 4.7 years.
RESULTS—The annual rate of the primary outcome was 2.2% in the fenofibrate group and 2.4%
in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval [CI], 0.79
to 1.08; P = 0.32). There were also no significant differences between the two study groups with
respect to any secondary outcome. Annual rates of death were 1.5% in the fenofibrate group and
1.6% in the placebo group (hazard ratio, 0.91; 95% CI, 0.75 to 1.10; P = 0.33). Prespecified subgroup
analyses suggested heterogeneity in treatment effect according to sex, with a benefit for men and
possible harm for women (P = 0.01 for interaction), and a possible interaction according to lipid
subgroup, with a possible benefit for patients with both a high baseline triglyceride level and a low
baseline level of high-density lipoprotein cholesterol (P = 0.057 for interaction).
CONCLUSIONS—The combination of fenofibrate and simvastatin did not reduce the rate of fatal
cardiovascular events, nonfatal myocardial infarction, or nonfatal stroke, as compared with
simvastatin alone. These results do not support the routine use of combination therapy with
fenofibrate and simvastatin to reduce cardiovascular risk in the majority of high-risk patients with
type 2 diabetes. (ClinicalTrials.gov number, NCT00000620.)
Patients with type 2 diabetes mellitus have an increased incidence of atherosclerotic
cardiovascular disease.1–4 This increase is attributable, in part, to associated risk factors,
including hypertension and dyslipidemia. The latter is characterized by elevated plasma
triglyceride levels, low levels of high-density lipoprotein (HDL) cholesterol, and small, dense
low-density lipoprotein (LDL) particles.5,6 The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) study was designed to test the effect of intensive treatment of blood
glucose and either blood pressure or plasma lipids on cardiovascular outcomes in 10,251
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patients with type 2 diabetes who were at high risk for cardiovascular disease. Here we present
the findings of the ACCORD lipid trial (ACCORD Lipid).
Although statins are efficacious in patients with type 2 diabetes, rates of cardiovascular events
remain elevated in such patients even after statin treatment.7–9 Fibrate therapy in patients with
type 2 diabetes reduced the rate of coronary heart disease events in the Veterans Affairs HDL
Intervention Trial (VA-HIT; ClinicalTrials.gov number, NCT00035711)10 but not in the
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial (Current Controlled
Trials number, ISRCTN64783481).11 However, a post hoc analysis of data from the FIELD
study suggested a benefit for patients with both elevated triglyceride levels and low HDL
cholesterol levels.12 Previous fibrate studies in subjects with diabetes10,11 or in those without
diabetes13–15 did not address the role of such drugs in patients receiving statin therapy. The
hypothesis that we tested in ACCORD Lipid was that in high-risk patients with type 2 diabetes,
combination treatment with a fibrate (both to raise HDL cholesterol levels and to lower
triglyceride levels) and a statin (to reduce LDL cholesterol levels) would reduce the rate of
cardiovascular events, as compared with treatment with a statin alone.
METHODS
STUDY DESIGN
The rationale and designs for the various components of ACCORD have been reported
previously.16–20 The ACCORD study was a randomized trial conducted at 77 clinical sites
organized into seven networks in the United States and Canada. (For a full list of participating
institutions and investigators, see Section 20 in Supplementary Appendix 1, available with the
full text of this article at NEJM.org The trial was sponsored by the National Heart, Lung, and
Blood Institute (NHLBI), and the protocol was approved by a review panel at the NHLBI, as
well as by the institutional review board or ethics committee at each center.
In the ACCORD study, all patients were randomly assigned to receive either intensive glycemic
control (targeting a glycated hemoglobin level below 6.0%) or standard therapy (targeting a
glycated hemoglobin level of 7.0 to 7.9%). The results of this comparison have been reported
previously.20 A subgroup of patients in the ACCORD study were also enrolled in the ACCORD
Lipid trial and underwent randomization, in a 2-by-2 factorial design, to receive simvastatin
plus either fenofibrate or placebo. Randomization occurred between January 11, 2001, and
October 29, 2005. End-of-study visits were scheduled between March and June 2009.
Additional details regarding the trial protocol and amendments are provided in Supplementary
Appendix 2, also available with the full text of this article at NEJM.org.
ELIGIBILITY
All patients in the ACCORD study had type 2 diabetes and a glycated hemoglobin level of
7.5% or more. If patients had evidence of clinical cardiovascular disease, the age range was
limited to 40 to 79 years; if they had evidence of subclinical cardiovascular disease or at least
two additional cardiovascular risk factors, the age range was compressed to 55 to 79 years.
Patients were specifically eligible to participate in the lipid trial if they also had the following:
an LDL cholesterol level of 60 to 180 mg per deciliter (1.55 to 4.65 mmol per liter), an HDL
cholesterol level below 55 mg per deciliter (1.42 mmol per liter) for women and blacks or
below 50 mg per deciliter (1.29 mmol per liter) for all other groups, and a triglyceride level
below 750 mg per deciliter (8.5 mmol per liter) if they were not receiving lipid therapy or below
400 mg per deciliter (4.5 mmol per liter) if they were receiving lipid therapy. All patients
provided written informed consent. Additional details regarding eligibility and the protocol for
the enrollment of patients are available in Section 3 in Supplementary Appendix 1.
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Randomization was performed centrally on the trial’s Web site with the use of permuted blocks
to maintain concealment of study-group assignments. Open-label simvastatin therapy began
at the randomization visit, and the masked administration of either fenofibrate or placebo began
1 month later. The initial dose of simvastatin complied with national lipid guidelines at the
time the study began.21 The dose of simvastatin was modified over time in response to changing
guidelines (see Section 6 in Supplementary Appendix 1).18
At the start of the trial, the dose of fenofibrate was 160 mg per day. Because of a rise in serum
creatinine levels in some patients while receiving this dose of fenofibrate,22 starting in 2004,
the dose of fenofibrate was adjusted according to the estimated glomerular filtration rate (GFR)
with the use of the abbreviated Modification of Diet in Renal Disease (MDRD) equation (see
Section 7 in Supplementary Appendix 1).23
A fasting plasma lipid profile was measured at the ACCORD central laboratory at 4, 8, and 12
months after randomization, annually thereafter, and at the end of the study. Safety profiles,
including liver-function tests and measurements of creatine kinase levels, were determined at
1, 4, 8, and 12 months after randomization and annually thereafter. If symptoms or signs
suggestive of drug-induced toxic effects developed, tests of liver function (including
measurement of alanine aminotransferase), creatine kinase, or both were obtained. If liver-
function values were elevated, lipid medications were temporarily discontinued; if creatine
kinase values were elevated, lipid medications were permanently discontinued.
PRESPECIFIED OUTCOMES
The prespecified primary outcome was the first occurrence of a major cardiovascular event,
including nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.
Secondary outcomes included the combination of the primary outcome plus revascularization
or hospitalization for congestive heart failure (termed the “expanded macrovascular
outcome”); a combination of a fatal coronary event, nonfatal myocardial infarction, or unstable
angina (termed “major coronary disease events”); nonfatal myocardial infarction; fatal or
nonfatal stroke; nonfatal stroke; death from any cause; death from cardiovascular causes; and
hospitalization or death due to heart failure. Definitions of each prespecified outcome and
methods of ascertainment are detailed in Section 8 in Supplementary Appendix 1.
STUDY OVERSIGHT
Fenofibrate and matching placebo were donated by Abbott Laboratories; simvastatin was
donated by Merck. The drug manufacturers had no role in the design of the study, in the accrual
or analysis of the data, or in the preparation of the manuscript. All authors vouch for the
accuracy and completeness of the reported data.
STATISTICAL ANALYSIS
The study was designed to recruit 5800 patients, with a power of 87% to detect a 20% reduction
in the rate of the primary outcome for patients in the fenofibrate group, as compared with
placebo, assuming a two-sided alpha level of 0.05, a primary outcome rate of 2.4% per year in
the placebo group, and an average follow-up of approximately 5.6 years for patients who did
not have an event. All statistical analyses were conducted at the coordinating center with the
use of S-Plus software, version 8.0 (Insightful) or SAS software, version 9.1 (SAS Institute).
Baseline characteristics were compared between study groups with the use of the chi-square
test, Fisher’s exact test, Wilcoxon rank-sum test, and two-sample t-tests. The incidence of key
safety outcomes was compared with the use of Fisher’s exact test.
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Analyses of primary and secondary outcomes were performed with the use of time-to-event
methods, according to the intention-to-treat principle, and occurrences of outcomes were
compared with the use of hazard ratios and 95% confidence intervals. Two-sided P values were
obtained from likelihood ratio tests from Cox proportional-hazards regression analyses. The
Cox models contained a term representing study-group assignment plus terms for the following
prespecified variables: assignment to the intensive glycemic intervention, the seven clinical-
center networks, and the presence or absence of a previous cardiovascular event. Between-
group differences were also examined in prespecified subgroups on 10 baseline characteristics
(see Section 9 in Supplementary Appendix 1). Event rates are expressed as the percentage of
events per years of follow-up, taking into account the censoring of follow-up data. Kaplan–
Meier estimates were used to obtain the proportion of patients who had an event during follow-
up.
The primary outcome and total rates of death were monitored by the data and safety monitoring
board, using O’Brien–Fleming boundaries determined by the Lan–DeMets approach. For the
primary outcome and rates of death, P values have been adjusted to account for the number,
timing, and results of interim analyses. Further details regarding the analytic methods are
available in Section 11 in Supplementary Appendix 1.
RESULTS
STUDY PATIENTS
A total of 5518 patients were enrolled in the ACCORD Lipid study, with 2765 assigned to
receive fenofibrate plus simvastatin and 2753 assigned to receive placebo plus simvastatin.
Baseline characteristics were similar between the two groups (Table 1). The mean age was 62
years, and 31% of the patients were female. Thirty-seven percent had a history of a
cardiovascular event, and about 60% were taking a statin before enrollment.
The mean duration of follow-up was 4.7 years for the primary outcome and 5.0 years for total
rates of death. At the final study visit, 77.3% of the patients in the fenofibrate group and 81.3%
of those in the placebo group were taking their assigned medication. At the end of the study,
approximately 80% of patients were still taking simvastatin in each group, and an additional
6% were taking an alternative study-approved agent for lowering LDL cholesterol. Additional
details related to adherence are in presented in Section 12 in Supplementary Appendix 1. The
average daily dose of simvastatin during the follow-up period was 22.3 mg in the fenofibrate
group and 22.4 mg in the placebo group.
SAFETY
Elevations of creatine kinase of more than 10 times the upper limit of the normal range at any
time during the trial occurred in 10 patients (0.4%) in the fenofibrate group and 9 (0.3%) in
the placebo group (for details, see Section 13 in Supplementary Appendix 1). An elevation in
alanine aminotransferase of more than three times the upper limit of the normal range occurred
in 52 patients (1.9%) in the fenofibrate group and 40 (1.5%) in the placebo group.
As noted in other fenofibrate trials,11,22 mean serum creatinine levels increased from 0.93 to
1.10 mg per deciliter (82 to 97 µmol per liter) in the fenofibrate group within the first year and
remained relatively stable thereafter. In the placebo group, mean serum creatinine levels
increased from 0.93 to 1.04 mg per deciliter (82 to 92 µmol per liter) during the course of the
trial (see Section 15 in Supplementary Appendix 1). The study drug was discontinued by 66
patients (2.4%) in the fenofibrate group and 30 (1.1%) in the placebo group because of a
decrease in the estimated GFR. At the last clinic visit, 440 patients (15.9%) in the fenofibrate
group and 194 (7.0%) in the placebo group were receiving a reduced dose of either fibrate or
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placebo because of a decreased estimated GFR. There was no significant between-group
difference in the incidence of both hemodialysis and end-stage renal disease (75 patients in the
fenofibrate group vs. 77 in the placebo group). There was a lower incidence of both
microalbuminuria and macroalbuminuria in the fenofibrate group than in the placebo group
(see Section 13 in Supplementary Appendix 1).
PLASMA LIPIDS
By the end of the study, the mean LDL cholesterol level fell from 100.0 to 81.1 mg per deciliter
(2.59 to 2.10 mmol per liter) in the fenofibrate group and from 101.1 to 80.0 mg per deciliter
(2.61 to 2.07 mmol per liter) in the placebo group (Fig. 1, and Section 16 in Supplementary
Appendix 1). Mean HDL cholesterol levels increased from 38.0 to 41.2 mg per deciliter (0.98
to 1.07 mmol per liter) in the fenofibrate group and from 38.2 to 40.5 mg per deciliter (0.99 to
1.05 mmol per liter) in the placebo group. Median plasma triglyceride levels decreased from
164 to 122 mg per deciliter (1.85 to 1.38 mmol per liter) in the fenofibrate group and from 160
to 144 mg per deciliter (1.81 to 1.63 mmol per liter) in the placebo group.
CLINICAL OUTCOMES
The annual rate of the primary outcome was 2.2% in the fenofibrate group, as compared with
2.4% in the placebo group (hazard ratio in the fenofibrate group, 0.92; 95% confidence interval
[CI], 0.79 to 1.08; P = 0.32 after adjustment for monitoring) (Table 2 and Fig. 2). Hazard ratios
for the secondary outcomes, including the individual components of the primary outcome,
ranged from 0.82 to 1.17 (P≥0.10 for all comparisons) (Table 2). Annual rates of death from
all causes were 1.5% in the fenofibrate group and 1.6% in the placebo group (hazard ratio,
0.91; 95% CI, 0.75 to 1.10; P = 0.33 for the adjusted comparison). Specific causes of death
and enlarged versions of the Figure 2 insets are presented in Sections 17 and 18 in
Supplementary Appendix 1.
Study-group effects on the primary outcome across prespecified baseline subgroups are shown
in Figure 3. Only sex showed evidence of an interaction according to study group: the primary
outcome for men was 11.2% in the fenofibrate group versus 13.3% in the placebo group,
whereas the rate for women was 9.1% in the fenofibrate group versus 6.6% in the placebo
group (P = 0.01 for interaction). There was also a nonsignificant suggestion of heterogeneity
when patients who had a triglyceride level in the highest third (≥204 mg per deciliter [≥2.30
mmol per liter]) and an HDL cholesterol level in the lowest third (≤34 mg per deciliter [≤0.88
mmol per liter]) were compared with all the other patients (P = 0.057 for interaction). In this
subgroup of patients with high triglyceride levels and low HDL cholesterol levels, the primary
outcome rate was 12.4% in the fenofibrate group, versus 17.3% in the placebo group, whereas
such rates were 10.1% in both study groups for all other patients.
DISCUSSION
In this trial, we tested the hypothesis that the use of fenofibrate to increase plasma HDL
cholesterol levels and to reduce plasma triglyceride levels in patients with type 2 diabetes who
were already receiving simvastatin therapy would result in an additional cardiovascular benefit,
as compared with simvastatin therapy alone. However, the rates of the primary outcome did
not differ significantly between the fenofibrate group and the placebo group during 4.7 years
of treatment and follow-up.
When a study does not support the central hypothesis, it is critical to examine potential reasons
for this outcome. One possibility is that the addition of fenofibrate to statin therapy benefited
only certain subgroups of patients and that other subgroups that did not benefit diluted the
overall effect. Our study was part of a factorial design to simultaneously test the effects of
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intensive glycemic control17,20 and combination lipid therapy on cardiovascular outcomes. To
allow for efficient enrollment of the entire cohort of 10,000 patients while including a group
for whom the results of the lipid trial could be widely extrapolated, we used broader inclusion
criteria for plasma lipid levels than might have been used if the lipid trial had been an
independent study.
A second possibility is that the trial might have had fewer events than anticipated. However,
the annual rate of 2.4% in the placebo group was the rate used in the power calculations.
Another possibility is poor adherence to the experimental protocol. However, adherence at the
end of the study was approximately 80% in both the fenofibrate and placebo groups and 80%
for simvastatin. Furthermore, unlike the FIELD study, in which there was a disproportionate
drop-in to statin therapy in the placebo group,11 the prevalence of statin therapy in our study
was similar in the fenofibrate and placebo groups. A fourth possibility is that fenofibrate is not
as effective as gemfibrozil, which showed benefit in the Helsinki Heart Study (HHS) and VA-
HIT,13,15 studies in which there was no background statin therapy.
In examined subgroups, only sex had a significant interaction with treatment: men seemed to
benefit from fenofibrate therapy, whereas there was a trend toward harm among women. This
is in contrast to the results of the FIELD study, in which there was no significant interaction
effect between treatment and sex on outcome.11
There was also a suggestion of heterogeneity according to baseline lipid levels: patients who
had both a triglyceride level in the highest third and an HDL cholesterol level in the lowest
third (which we termed the subgroup with dyslipidemia) appeared to benefit from fenofibrate,
whereas all other patients receiving fenofibrate did not. The mean baseline HDL cholesterol
level in the subgroup with dyslipidemia was 29.5 mg per deciliter (0.76 mmol per liter), and
the median triglyceride level was 284 mg per deciliter (3.21 mmol per liter), in contrast to the
rest of the patients, in whom the mean HDL cholesterol level was 39.9 mg per deciliter (1.03
mmol per liter) and the median triglyceride level was 144 mg per deciliter (1.63 mmol per
liter). From baseline to 4 months in the fenofibrate group, the HDL cholesterol level rose 12.9%
and the triglyceride level fell 35.0% among patients in the subgroup with dyslipidemia, as
compared with a 7.3% rise in the HDL cholesterol level and a 24.1% decrease in the triglyceride
level among all other patients receiving fenofibrate. The treatment interaction according to sex
for the entire ACCORD Lipid cohort was not observed in the subgroup with dyslipidemia (data
not shown).
The results for patients in the subgroup with dyslipidemia are similar to those in post hoc
subgroup analyses performed in three of four major fibrate trials, including HHS,24 the
Bezafibrate Infarction Prevention (BIP) trial,14 and the FIELD trial12 (see Section 19 in
Supplementary Appendix 1 for details). Our subgroup results and those of these previous trials
support the view that the addition of fenofibrate to a statin may benefit patients with type 2
diabetes who have substantial dyslipidemia. The use of combination fibrate–statin therapy in
such patients is consistent with current guidelines that recommend treatment for patients with
hypertriglyceridemia and low HDL cholesterol levels that persist despite statin therapy.25
Previous studies11,22 have raised concern about increases in serum creatinine levels during
fenofibrate treatment. Serum creatinine levels increased in the fenofibrate group soon after
randomization but thereafter remained constant, as compared with those in the placebo group.
In the FIELD study, there was a return of serum creatinine to baseline levels by 8 weeks after
the end of the trial.11 In our study, there was no significant difference in the incidence of end-
stage renal disease or need for dialysis between the fenofibrate group and the placebo group.
There was a reduction in both microalbuminuria and macroalbuminuria in the fenofibrate
group. There has also been longstanding concern regarding an increased risk of myositis or
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rhabdomyolysis when fibrates are added to statins.26,27 No evidence for such a risk was noted
in our study, a finding that was compatible with evidence that fenofibrate, in contrast to
gemfibrozil, does not increase plasma concentrations of statins.28
In conclusion, we found that combination therapy with the use of fenofibrate and simvastatin
(at a daily dose of 40 mg or less) did not reduce rates of cardiovascular disease, as compared
with simvastatin alone. Our findings do not support the use of combination fibrate–statin
therapy, rather than statin therapy alone, to reduce cardiovascular risk in the majority of patients
with type 2 diabetes who are at high risk for cardiovascular disease.
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Figure 1. Lipid Values
Shown are mean plasma levels of total cholesterol (Panel A), low-density lipoprotein (LDL)
cholesterol (Panel B), and high-density lipoprotein (HDL) cholesterol (Panel C) and median
levels of triglycerides (Panel D) at baseline, 4 months, 8 months, 1 year, and annually thereafter.
Nominal P values for differences between the study groups at 4 months and at the end of the
study were, respectively: total cholesterol, P<0.001 and P = 0.02; LDL cholesterol, P = 0.11
and P = 0.16; HDL cholesterol, P<0.001 and P=0.01; and triglycerides, P<0.001 for both
comparisons with the use of nonparametric tests. End-of-study visits were those that occurred
in early 2009 and included follow-up at years 4, 5, 6, and 7. The I bars represent 95% confidence
intervals. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To
convert the values for triglycerides to millimoles per liter, multiply by 0.01129.
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Figure 2. Kaplan-Meier Analyses of the Primary Outcome, Expanded Macrovascular Outcome,
and Death
Shown are the cumulative incidence of the primary outcome (nonfatal myocardial infarction,
nonfatal stroke, or death from cardiovascular causes) (Panel A), the expanded macrovascular
outcome (a combination of the primary outcome plus revascularization or hospitalization for
congestive heart failure) (Panel B), and death from any cause (Panel C) or from cardiovascular
causes (Panel D) during follow-up. The insets show close-up versions of the graphs in each
panel.
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Figure 3. Hazard Ratios for the Primary Outcome in Prespecified Subgroups
The horizontal bars represent 95% confidence intervals, and the vertical dashed line indicates
the overall hazard ratio. The size of each square is proportional to the number of patients. P
values are for tests for interaction. To convert the values for cholesterol to millimoles per liter,
multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply
by 0.01129.
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(N = 2753) P Value
Age — yr 62.3±6.8 62.2±6.7 62.3±6.9 0.69
Female sex — no. (%) 1694 (30.7) 851 (30.8) 843 (30.6) 0.90
Race or ethnic group — no. (%)†
 White 3774 (68.4) 1909 (69.0) 1865 (67.7) 0.30
 Black 834 (15.1) 392 (14.2) 442 (16.1) 0.05
 Hispanic 407 (7.4) 213 (7.7) 194 (7.0) 0.35
Education — no. (%) 0.19
 Less than high school 750 (13.6) 394 (14.2) 356 (12.9)
 High-school graduate or GED 1433 (26.0) 712 (25.8) 721 (26.2)
 Some college 1827 (33.1) 885 (32.0) 942 (34.2)
 College degree or higher 1505 (27.3) 772 (27.9) 733 (26.6)
 Missing data 3 (<0.1) 2 (0.1) 1 (<0.1)
Previous cardiovascular event — no. (%) 2016 (36.5) 1008 (36.5) 1008 (36.6) 0.90
Previous congestive heart failure — no. (%) 291 (5.3) 151 (5.5) 140 (5.1) 0.54
Cigarette-smoking status — no. (%) 0.42
 Current 803 (14.6) 410 (14.8) 393 (14.3)
 Former 2546 (46.2) 1292 (46.7) 1254 (45.6)
 Never 2161 (39.2) 1059 (38.3) 1102 (40.0)
 Missing data 8 (0.1) 4 (0.1) 4 (0.1)
Weight — kg 94.8±18.7 94.5±18.5 95.2±18.8 0.21
Body-mass index‡ 32.3±5.4 32.2±5.4 32.4±5.4 0.32
Blood pressure — mm Hg
 Systolic 133.9±17.8 133.8±17.7 134.0±17.9 0.79
 Diastolic 74.0±10.8 73.9±10.7 74.0±10.9 0.58
Medications — no. (%)
 Insulin 1836 (33.3) 919 (33.2) 917 (33.3) 0.95
 Metformin 3420 (62.0) 1712 (61.9) 1708 (62.0) 0.92
 Any sulfonylurea 2892 (52.4) 1440 (52.1) 1452 (52.7) 0.62
 Any thiazolidinedione 973 (17.6) 480 (17.4) 493 (17.9) 0.59
 Angiotensin-converting–enzyme inhibitor 2967 (53.8) 1473 (53.3) 1494 (54.3) 0.46
 Angiotensin-receptor blocker 838 (15.2) 405 (14.6) 433 (15.7) 0.26
 Aspirin 3106 (56.3) 1583 (57.3) 1523 (55.3) 0.15
 Beta-blocker 1798 (32.6) 912 (33.0) 886 (32.2) 0.53
 Any thiazide diuretic 1473 (26.7) 740 (26.8) 733 (26.6) 0.91
 Statin 3299 (59.8) 1641 (59.3) 1658 (60.2) 0.51
 Any lipid-lowering agent 3558 (64.5) 1773 (64.1) 1785 (64.8) 0.58




















(N = 2753) P Value
Duration of diabetes — yr
 Median 9 10 9 0.83
 Interquartile range 5–15 5–15 5–15
Glycated hemoglobin — %
 Mean 8.3±1.0 8.3±1.0 8.3±1.0 0.52
 Median 8.1 8.1 8.1
 Interquartile range 7.6–8.8 7.6–8.8 7.5–8.8
Fasting plasma glucose — mg/dl 175.8±54.9 176.5±54.5 175.1±55.3 0.38
Amputation due to diabetes — no. (%) 110 (2.0) 59 (2.1) 51 (1.9) 0.45
Potassium — mg/dl 4.5±0.4 4.5±0.4 4.5±0.4 0.31
Serum creatinine — mg/dl 0.9±0.2 0.9±0.2 0.9±0.2 0.96
Estimated glomerular filtration rate — no. (%)
 30–49 ml/min/1.73 m2 141 (2.6) 71 (2.6) 70 (2.5) 0.89
 >50 ml/min/1.73 m2 5347 (97.4) 2668 (97.4) 2679 (97.5)
Plasma cholesterol — mg/dl
 Total 175.2±37.3 174.7±36.8 175.7±37.9 0.36
 Low-density lipoprotein 100.6±30.7 100.0±30.3 101.1±31.0 0.15
 High-density lipoprotein 38.1±7.8 38.0±7.8 38.2±7.8 0.25
Plasma triglyceride — mg/dl
 Median 162 164 160 0.15
 Interquartile range 113–229 114–232 112–227
*
Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for glucose to millimoles per liter,
multiply by 0.055551. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to
millimoles per liter, multiply by 0.01129. To convert the values for potassium to millimoles per liter, multiply by 0.2558. To convert the values for
creatinine to micromoles per liter, multiply by 88.4. GED denotes general equivalency diploma.
†
Race or ethnic group was self-reported, and patients could check multiple categories.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
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